Pioneering the future of regenerative medicine with iPS cell-derived cardiomyocyte patches to deliver innovative therapeutic options.
サブタイトル画像サンプルテキスト
サンプルテキスト
News
-
ReleaseCUORIPS Inc. Announces Acceptance of Abstract on Groundbreaking Cardiac Regenerative Therapy at AHA's BCVS 2026
-
ReleaseNew Insights into Cardiac Regeneration: hiPSC-derived Cardiomyocytes Patches Remodel the Injured Heart
-
ReleaseWorld’s First iPSC-Derived Cardiomyocyte Therapy for Heart Failure Receives Conditional Approval in Japan
-
ReleaseWe are pleased to announce our participation in Japan Health, to be held from Wednesday, June 25 to Friday, June 27, 2025.
-
ReleaseAnnouncement of Application for Approval of Manufacturing and Marketing of Human (Allogeneic) iPS Cell-derived Cardiomyocyte Patches
-
Features01RiHEARTRIHEART®: A pioneering iPS cell-derived therapy for severe heart failure, developed to meet unmet medical needs. -
02
Consortium(VMaCS)Subsidized by the Ministry of Economy, Trade and Industry (METI), we have established a national development consortium to implement a next-generation mass cell manufacturing system in Japan, accelerating the development of advanced modalities.
By leveraging our proprietary manufacturing technologies and expertise gained from iPSC-derived cardiomyocyte sheets, we unite the strengths, technical capabilities, and insights of leading private enterprises. Together, we empower drug discovery startups to scale globally and capture the expanding international market.
-
03Expo LegacyBridging the innovation of the Osaka-Kansai Expo with the future of medicine. Discover how Cuorips is shaping the 'Expo Legacy' by exploring our archived presentation on the real-world implementation of our next-generation technologies.
ABOUT US
